Pembrolizumab as first-line treatment for recurrent or metastatic head and neck squamous cell carcinoma: a multi-institutional DAHANCA cohort study
In this real-world multi-centre study, pembrolizumab demonstrated efficacy equivalent to the registration studies in two independent cohorts.
Authors
- Kasper Toustrup
- Zsuzsanna Iyizoba-Ebozue (ORCID: https://orcid.org/0000-0002-9839-4532)
- Kinga Nowicka-Matus (ORCID: https://orcid.org/0000-0002-0625-1172)
- Jesper Grau Eriksen (ORCID: https://orcid.org/0000-0002-1145-6033)
- Niels Gyldenkerne
- Trine Tramm (ORCID: https://orcid.org/0000-0003-3894-4552)
- Sebastian Søby
- Camilla Kjær Lønkvist (ORCID: https://orcid.org/0009-0003-9692-0839)
- Anita Gothelf (ORCID: https://orcid.org/0000-0002-7077-7937)
- S. F. I. Mihaela
- Maria Andersen (ORCID: https://orcid.org/0000-0003-2883-2450)
- Christian Maare (ORCID: https://orcid.org/0000-0002-9698-2082)
- Robin Prestwich (ORCID: https://orcid.org/0000-0002-7872-2826)
- Danny Ulahannan
Institutions
- University of Leeds (GB)
- Aarhus University (DK)
- Aalborg University Hospital (DK)
- St James's University Hospital (GB)
- Odense University Hospital (DK)
- Herlev Hospital (DK)
- Aarhus University Hospital (DK)
- Copenhagen University Hospital (DK)
Publication Details
- Journal
- Acta Oncologica
- Published
- 2025-09-21
- DOI
- https://doi.org/10.2340/1651-226x.2025.44327
- Citations
- 1
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 1.05